Fenofibrate effective in treatment of COVID-19

Hebrew University interventional open-label study led by Prof. Yaakov Nahmias on 15 severe COVID-19 patients requiring oxygen support shows that 145 mg/day fenofibrate (TriCor) reduced inflammation in 48 hours and eliminated the need for oxygen support within 5 to 7 days of hospitalization.

The clinical study results follow earlier reports of the group showing lipid accumulation in human lungs and a large multi-center observational study that showed fibrate patients were protected from severe COVID-19

For manuscript and clinical information see Ehrlich et al. Metabolic Regulation of SARS-CoV-2 Infection at https://www.researchsquare.com/article/rs-770724/v1